27th World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI), November 21-23, 2019, Paris

On Friday November 22, 2019, Herjan Coelingh Bennink from Pantarhei Oncology lectured during the session: Breast cancer epidemic and hormonal replacement: What is the relationship?

The title of this special countercurrent lecture was: Treatment of advanced breast cancer with high dose estrogens.

For more information please read the abstract.

13th European Society of Gynecology (ESG) Congress, October 16-19, 2019, Vienna, Austria

On Thursday October 17, 2019, Herjan Coelingh Bennink of Pantarhei Oncology lectured on: “Estetrol for the treatment of advanced breast cancer” in a symposium entitled “Breast cancer: new challenges in diagnosis, pathogenesis and therapy”. The symposium was chaired by Xiangyan Ruan and Kerstin Rhiem.

For more information, please read the abstract.

Pantarhei Oncology Change of Address

Beginning of September, Pantarhei Oncology has moved the office to a new building. The new address is Boulevard 17, 3707 BK Zeist, the Netherlands. For more information, see change-of-address.

Pantarhei Oncology New Address

12th European Congress on Menopause and Andropause, May 15-17, 2019, Berlin

On Thursday May 16, 2019, Pantarhei Oncology sponsored a symposium entitled “Treatment of Breast Cancer and Prostate Cancer with the Fetal Estrogen Estetrol”. Lectures were presented by Herjan Coelingh Bennink (The profile of the fetal estrogen estetrol [E4]), Hans Georg Lenhard (Treatment of advanced breast cancer with E4) and Frans Debruyne (Treatment of advanced prostate cancer with E4). The session was chaired by Tomasso Simoncini and Yvette Zimmerman.

Interview met Yvette Zimmerman en Olav Andriesse in BiotechNEWS & Life Sciences

Pantarhei Bioscience (sinds 2001) werd in 2014 uitgebreid met een succesvolle Oncology-tak en diende in de afgelopen jaren meer dan 220 patenten in. Een actieve onderneming, volop in ontwikkeling -niet voor niets Panta Rhei – alles stroomt- met een diepgewortelde missie en visie: “Pantarhei ontwikkelt veilige en effectieve nieuwe geneesmiddelen op basis van bestaande menselijke moleculen tot en met “proof-of-concept” bij de mens. Met deze strategie zijn we 18 jaar geleden begonnen en is succesvol gebleken,” aldus de nieuwe CEO Yvette Zimmerman. Lees hier het artikel.

Contribution of Pantarhei Oncology to the 18th World Congress of the IAHR

Contribution of Pantarhei Oncology to the 18th World Congress of the International Academy of the Human Reproduction (IAHR), April 3-6, 2019 in Dublin by an invited lecture of Herjan Coelingh Bennink.

On Thursday April 4, 2019, a key lecture entitled “Estrogens, Estetrol and Breast Cancer” was given by Herjan Coelingh Bennink, President of Pantarhei Oncology during a scientific session “Oncology, Breast and Gynecological Surgery”. The session was chaired by by Andrea Genazzani. For more information, please read the abstract.

Yvette Zimmerman nieuwe CEO Pantarhei Bioscience: “Wij ontdekken veilige en effectieve nieuwe geneesmiddelen op basis van bestaande menselijke moleculen.”

Het Nederlandse biofarmaceutische bedrijf Pantarhei Bioscience heeft met ingang van januari 2019 haar Chief Operating Officer (COO) Yvette Zimmerman benoemd tot Chief Executive Officer (CEO). De oprichter en vorige CEO van Pantarhei, Herjan Coelingh Bennink, is trots op zijn opvolgster: “Yvette is een zeer ervaren ontwikkelaar van nieuwe geneesmiddelen, gemotiveerd door wat echt belangrijk is voor zieke mensen en wat wetenschappelijk vernieuwend is.”

Pantarhei bestaat nu 18 jaar en heeft in die tijd meer dan 220 patenten ingediend. Oorspronkelijk was Pantarhei gericht op het ontwikkelen van nieuwe geneesmiddelen op het gebied van Women’s Health. Sinds de oprichting van het dochterbedrijf Pantarhei Oncology in 2014, is de focus verlegd naar nieuwe hormonale behandelingen van kanker, met name borst- en prostaatkanker.

Lees verder: Persbericht Nieuwe CEO Pantarhei Bioscience

 

 

Yvette Zimmerman new CEO Pantarhei Bioscience: “We find safe and effective new treatments using existing human molecules.”

Pantarhei Bioscience, the Dutch biopharmaceutical company, is pleased to announce the appointment of Yvette Zimmerman as Chief Executive Officer (CEO), with effect from January 2019. The founder of Pantarhei Herjan Coelingh Bennink speaks proudly about his successor: “Yvette is a very experienced drug developer and driven by what is really important for people and scientifically sound.”

During the 18 years of its existence, Pantarhei has filed more than 220 patents. Initially Pantarhei developed new medicines for Women’s Health. Following the foundation of the subsidiary company Pantarhei Oncology in 2014, the focus has been redirected to new treatment concepts for endocrine cancer, especially breast and prostate cancer.

Read more: Press Release New CEO Pantarhei Bioscience

 

Fetal estrogen Estetrol effective for breast cancer treatment

Pantarhei Oncology announces favorable efficacy results of the fetal estrogen Estetrol in women with advanced breast cancer.

Press release Pantarhei Oncology December 6 2018

Zwangerschapshormoon Estetrol effectief bij behandeling van borstkanker

Pantarhei Oncology rapporteert positieve resultaten van de behandeling van borstkanker met het zwangerschapshormoon Estetrol.

 Persbericht Pantarhei Oncology 6 december 2018

IMPRINT

Pantarhei Oncology BV | Boulevard 17 | 3707 BK Zeist | The Netherlands
Phone: +31 (0)30 6 985 020 | Email: info@pantarheioncology.nl

DISCLAIMER

The information contained in this website is for general information purposes only. The information is provided by Pantarhei Oncology and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

SOCIAL MEDIA